Inhibikase Therapeutics Inc. Common Stock
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It offers products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
IKT Overview
Sector |
Health Care |
Industry |
Biotechnology: Biological Products (No Diagnostic Substances) |
Previous Close |
$2.7800 |
Previous Close Volume |
27220 |
Latest News
- Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity 14 Nov 2024 08:55:31
- Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension 21 Oct 2024 09:25:54
- Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension 09 Oct 2024 09:25:52
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity 14 Aug 2024 16:26:16
- Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 07 Aug 2024 08:26:10
- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease 17 Jun 2024 08:26:19
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs 05 Jun 2024 08:26:26
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million 20 May 2024 08:11:14
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement 15 May 2024 09:11:14
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension 09 May 2024 08:11:26
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs 18 Apr 2024 16:56:23
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension 03 Apr 2024 08:26:17
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity 27 Mar 2024 16:26:32
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders 07 Mar 2024 08:41:31
- Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro 28 Feb 2024 16:11:44
- Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers 07 Feb 2024 07:56:16
- Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib 29 Jan 2024 09:11:34
- Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli 16 Jan 2024 16:11:33